A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from day one
- Coverage possible with two-week gap before premature birth
- Vaccination in the third trimester still provides meaningful protection for infants
Persuasive evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a extensive research programme conducted across England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing comprehensive and reliable data of the vaccine’s actual performance. The study’s findings have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The breadth of this investigation provides healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across varied populations and settings.
The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This stark contrast highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The drop in hospital admissions above 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospitalisations. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology measured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the threats
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed effectively. Parents often witness their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their compromised lungs. Whilst most infants recover with palliative treatment, a limited though important proportion perish from respiratory syncytial virus complications annually, making vaccination as prevention a critical public health objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV triggers lung inflammation, leading to serious respiratory problems in babies
- Nearly 50% of infants contract the infection in their first few months of life
- Symptoms vary between mild colds to life-threatening chest infections needing hospital treatment
- More than 20,000 UK infants require serious hospital care for RSV annually
- Few babies die from RSV related complications each year in the UK
Adoption rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have highlighted the value of pregnant women receiving their jab at the best time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.
The messaging from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional variations in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These regional differences reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts launching diverse outreach initiatives to engage with women during pregnancy
- Geographic variations in vaccine uptake rates across England demand focused enhancement
- Community health services adapting programmes to meet specific population needs
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness delivers tangible benefits for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this protective measure, the 80% drop in admissions equates to thousands of infants shielded from severe infection. Parents no longer face the troubling prospect of seeing their babies gasping for air or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has markedly changed the picture of neonatal respiratory health, offering expectant mothers a proactive tool to shield their most vulnerable children during those critical early months.
For families like that of Malachi, whose severe RSV infection caused severe brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s promotion of the jab highlights the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women in their third trimester, converting what was once an predictable seasonal threat into a manageable risk.